O-2545

O-2545
Legal status
Legal status	In general: unscheduled;
Identifiers
	IUPAC name (6aR,10aR)-6a,7,10,10a-Tetrahydro-3-[5-(1H-imidazol-1-yl)-1,1-dimethylpentyl]-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol;
CAS Number	874745-42-3 ;
ChemSpider	22938186 ;
CompTox Dashboard (EPA)	DTXSID30635364 ;
Chemical and physical data
Formula	C26H36N2O2
Molar mass	408.586 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC[C@H]2[C@@](Oc3c(c(cc(c3)C(CCCCn4cncc4)(C)C)O)[C@@H]2C1)(C)C;
	InChI InChI=1S/C26H36N2O2/c1-18-8-9-21-20(14-18)24-22(29)15-19(16-23(24)30-26(21,4)5)25(2,3)10-6-7-12-28-13-11-27-17-28/h8,11,13,15-17,20-21,29H,6-7,9-10,12,14H2,1-5H3/t20-,21-/m1/s1 ; Key:RZGSWWCABDVBGX-NHCUHLMSSA-N ;
	(what is this?) (verify)

O-2545 is an analgesic cannabinoid derivative created by Organix Inc. for use in scientific research. Unlike most cannabinoids discovered to date, it is water-soluble, which gives it considerable advantages over many related cannabinoids. It has high affinity for both CB₁ and CB₂ receptors, with K_i values of 1.5 nM at CB₁ and 0.32 nM at CB₂.^[1]

References

^ Martin BR, Wiley JL, Beletskaya I, Sim-Selley LJ, Smith FL, Dewey WL, Cottney J, Adams J, Baker J, Hill D, Saha B, Zerkowski J, Mahadevan A, Razdan RK (September 2006). "Pharmacological characterization of novel water-soluble cannabinoids". The Journal of Pharmacology and Experimental Therapeutics. 318 (3): 1230–9. doi:10.1124/jpet.106.104109. PMID 16757541.

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.

[pmid16757541-1] Martin BR, Wiley JL, Beletskaya I, Sim-Selley LJ, Smith FL, Dewey WL, Cottney J, Adams J, Baker J, Hill D, Saha B, Zerkowski J, Mahadevan A, Razdan RK (September 2006). "Pharmacological characterization of novel water-soluble cannabinoids". The Journal of Pharmacology and Experimental Therapeutics. 318 (3): 1230–9. doi:10.1124/jpet.106.104109. PMID 16757541.

[1]

See also

References